Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $16.67 Consensus Target Price from Brokerages

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has received a consensus rating of “Hold” from the four ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $16.67.

Several research analysts recently issued reports on ATRA shares. Mizuho raised Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and dropped their price objective for the stock from $25.00 to $18.00 in a research note on Friday, August 16th. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Finally, Canaccord Genuity Group increased their target price on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th.

Institutional Trading of Atara Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Delap Wealth Advisory LLC purchased a new stake in shares of Atara Biotherapeutics during the 1st quarter valued at $29,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Atara Biotherapeutics during the 2nd quarter valued at $53,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Atara Biotherapeutics during the 2nd quarter valued at $79,000. State Street Corp lifted its holdings in shares of Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the last quarter. Finally, FMR LLC lifted its holdings in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the last quarter. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Stock Down 2.8 %

Shares of NASDAQ:ATRA opened at $10.68 on Monday. Atara Biotherapeutics has a 52-week low of $6.50 and a 52-week high of $39.50. The stock has a market cap of $61.52 million, a P/E ratio of -0.41 and a beta of 0.50. The business’s 50 day moving average is $9.14 and its 200 day moving average is $10.11.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same period last year, the company earned ($16.50) EPS. On average, sell-side analysts anticipate that Atara Biotherapeutics will post -12.12 EPS for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.